Targeting the protein-protein interface pocket of Aurora-A-TPX2 complex: rational drug design and validation

Aurora-A is a novel therapeutic target that belongs to the serine/threonine kinase family of proteins. Several cancers are associated with gene amplification or over-expression of Aurora-A. The somatic mutation (S155R) in Aurora-A results in a loss of interaction with its binding partner TPX2. The S155R mutation thus leads to ectopic expression of Aurora-A, resulting in centrosome amplification, chromosomal instability, aneuploidy, and oncogenic transformations. In order to restore the interaction between mutant Aurora-A and TPX2, we predicted a binding pocket in the interface of the Aurora-A-TPX2 complex. We performed molecular docking of potential bioactive molecules of the Himalayan region at the predicted site. Alantolactone and Dactylose-A were selected as potential molecules that could bind to the interface pocket and restore the lost interaction between mutant Aurora-A and TPX2. The molecular docking results were validated by performing explicit long term molecular dynamics simulations (4.0 mu s) and MM-PBSA analysis. The molecular dynamics results confirmed that both the selected molecules could act as potent drugs to tackle the abnormal expression of Aurora-A manifested due to the somatic mutation (S155R).

Automated summary

Aurora-A is a novel therapeutic target associated with gene amplification or over-expression in cancers. By predicting a binding pocket, potential bioactive molecules were identified to restore lost interaction between mutant Aurora-A and TPX2, showing promise as potent drugs to tackle abnormal expression caused by somatic mutations.